The FDA has given the approval for Bydureon, which is the first weekly treatment for Type 2 Diabetes.
The drug, an injection, is actually a long-acting form of Byetta. This shot can be used in combination with diet and exercise to improve blood sugar control among people with Type 2 diabetes.
Bydureon, is manufactured by Alkermes PLC and Amylin Pharmaceuticals Inc. Initially the FDA had not approved this drug as there were concerns that it might increase the risk of heart problems. As part of the new approval, the FDA has asked the organization to conduct a study to gauge whether the drug actually elevates risk of heart disease.
John Buse, MD, PhD, professor of medicine, director of the Diabetes Care Center, and chief of the division of endocrinology at the University Of North Carolina School Of Medicine in Chapel Hill said, "With Bydureon, U.S. physicians and patients can now choose a therapy that offers continuous blood sugar control in just one dose per week."